Open AccessThe Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
Author(s) -
Jingjing Li,
Chuanyong Guo,
Jianye Wu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s310163
Subject(s) - peroxisome proliferator activated receptor , cirrhosis , nuclear receptor , peroxisome , transcription factor , fibrosis , microrna , receptor , hepatic fibrosis , pathogenesis , peroxisome proliferator , cancer research , medicine , bioinformatics , pharmacology , biology , gene , biochemistry
Liver fibrosis is a common link in the transformation of acute and chronic liver diseases to cirrhosis. It is of great clinical significance to study the factors associated with the induction of liver fibrosis and elucidate the method of reversal. Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear transcription factors that can be activated by peroxisome proliferators. PPARs play an important role in fibrosis of various organs, especially the liver, by regulating downstream targeted pathways, such as TGF-β, MAPKs, and NF-κB p65. In recent years, the development and screening of PPAR-γ ligands have become a focus of research. The PPAR-γ ligands include synthetic hypolipidemic and antidiabetic drugs. In addition, microRNAs, lncRNAs, circRNAs and nano new drugs have attracted research interest. In this paper, the research progress of PPAR-γ in the pathogenesis and treatment of liver fibrosis was discussed based on the relevant literature in recent years.